Retinoblastoma (RB) is a cancer in the retina that develops in children usually under the age of five and can cause blindness, loss of the affected eye, or death by metastasis, if not diagnosed and treated early. It arises as a result of bi‐allelic inactivation of the RB1 gene in a retinal cell that prevents the production of the pRB protein, causing uncontrollable cell proliferation in the retina. The Genetic Diagnostic Laboratory in the Perelman School of Medicine at the University of Pennsylvania has used Sanger sequencing to identify disease‐causing mutations in the RB1 gene in thousands of individuals diagnosed with bilateral retinoblastoma. Current testing focuses on coding regions and splice site consensus sequences, and various mutations have been found in 97% of individuals tested. This study aimed to identify pathogenic exonic or deep intronic mutations in the germline of six individuals which belong to the 3% of mutation‐negative cases. For three of these individuals, RNA isolated from the lymphocytes of the whole blood was converted into cDNA, RB1 transcript amplified with gene specific primers and sequenced by Sanger sequencing. The cDNA of RB1 had indicated one sample had a heterozygous deletion of exon 10, but the cause of the exonic deletion was unknown. To investigate this, several primer pairs were designed to amplify and sequence regions flanking the deleted region in the genomic DNA, and an inversion between exons 10 and 11 was suspected. For the other two patients, who are sisters, an exonic deletion of exon 2 was found but proven to be benign. For the other three individuals, previous Sanger sequencing of exons had not indicated the presence of any pathogenic mutations. An AmpliSeq panel of three hundred and four primer pairs was designed to amplify and sequence both coding and non‐coding regions spanning the RB1 gene. Amplicons were prepared using genomic DNA isolated from these three individuals and next generation sequencing on the Ion Torrent PGM platform was performed. Upon analysis, three pathogenic mutations present at low allele frequencies were identified in each individual. These were low frequency mosaic mutations that may not be detected through Sanger sequencing. Therefore, the AmpliSeq design panel can provide information about intronic mutations and low frequency mosaic mutations, and it can serve as an assay complimentary to Sanger sequencing when investigating missing mutations in RB1 gene.Support or Funding InformationJennifer Richards‐Yutz, Tappan Ganguly, Eric Toorens, Jennifer Rosado, Richard Grant, Kimberly Moran, Arupa Ganguly. Genetic Diagnostic Laboratory at the University of Pennsylvania, Philadelphia, PAThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.